Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
6.94
-0.17 (-2.39%)
At close: Jun 24, 2025, 4:00 PM
6.94
0.00 (0.00%)
Pre-market: Jun 25, 2025, 6:52 AM EDT
Unicycive Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
87.73M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
UNCY News
- 8 days ago - Unicycive Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewsWire
- 15 days ago - Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 6 weeks ago - Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia - GlobeNewsWire